Navigation Links
New Anal Cancer Therapy Fails to Improve Outcomes
Date:4/22/2008

Experimental use of cisplatin no better than standard treatment, researchers say

TUESDAY, April 22 (HealthDay News) -- Compared to the standard treatment regimen for anal canal cancer, the use of the chemotherapy drug cisplatin before other treatments didn't improve disease-free survival and resulted in a higher rate of colostomy procedures, says a U.S. study.

Currently, the preferred primary therapy for patients with anal canal cancer is chemoradiation (concurrent use of radiation and the anti-cancer drugs fluorouracil/mitomycin), which achieves a five-year survival rate of about 65 percent, according to background information in the study.

It's been suggested that reducing cancer in the primary tumor and in the lymph node or nodes prior to chemoradiation might improve disease-free survival. Pilot studies using cisplatin prior to chemoradiation showed promise.

In this new, randomized controlled trial, Dr. Jaffer A. Ajani, of the University of Texas M.D. Anderson Cancer Center in Houston, and colleagues compared treatment with fluorouracil plus mitomycin and radiation therapy to treatment with fluorouracil plus cisplatin and radiation therapy.

The findings from 644 patients showed a five-year, disease-free survival rate of 60 percent in the mitomycin group and 54 percent in the cisplatin group. The five-year overall survival rate was 75 percent in the mitomycin group and 70 percent in the cisplatin group. There were more cancer-related deaths in the cisplatin group (54) than in the mitomycin group (28).

The five-year, local-regional cancer recurrence and distant metastasis rates were 25 percent and 15 percent, respectively, for the mitomycin group and 33 percent and 19 percent, respectively, for the cisplatin group. Severe blood toxicity was worse in the mitomycin group. The cisplatin group had a higher rate of colostomy (19 percent vs. 10 percent).

"The question remains how to further improve disease-free and colostomy-free survival relative to the continued standard of concurrent chemoradiation with fluorouracil and mitomycin," the study authors wrote. "Options to explore included targeted agents (e.g., results with concurrent cetuximab plus radiation for head/neck cancer), dose escalation with intensity-modulated radiation plus concurrent chemotherapy, and surgical excision of residual cancer after concurrent chemoradiation at an earlier interval, when sphincter preservation may still be feasible in select patients."

The study was published in this week's issue of the Journal of the American Medical Association.

More information

The American Cancer Society has more about anal cancer.



-- Robert Preidt



SOURCE: Journal of the American Medical Association, news release, April 22, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Scientists discover a mechanism that can send cells on the road to cancer
2. Factors in Cancer Death Rates Stay Stagnant
3. Cancer Death Rates Stay Stagnant
4. OHSU Cancer Institute researcher identifies protein that helps predict prostate cancer survival
5. Phone counseling improves quality of life, immune systems of cervical cancer survivors
6. Prostate cancer screening program leads to bigger fall in death rates than surrounding areas
7. A stem cell type supposed to be crucial for angiogenesis and cancer growth does not exist?
8. Potential viral therapy weapon for difficult cancers is safe and effective in study
9. American Cancer Society report details cancer prevention efforts
10. Cancer could return unless stored ovarian tissue undergoes adequate testing before re-implantation
11. Cancer cells spread by releasing bubbles, according to an MUHC study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... ... Dr. Farhan Qureshi is an esteemed dentist who offers a full range of ... convenient office locations in Alexandria and Arlington, Virginia. Recently, Find Local Dentists has recognized ... This award confirms the fact that Dr. Qureshi’s patients have left highly favorable reviews ...
(Date:1/18/2017)... ... 18, 2017 , ... The Hear the World Foundation, a ... donation of cochlear implants. In February 2017, the first three children with profound ... of leading an independent life. This engagement builds on the support the Hear ...
(Date:1/18/2017)... ... 2017 , ... Floundering on New Year’s resolutions? Need an excuse to get ... reset. The U.S. Apple Association agrees and recommends starting each day with apples, ... to heart disease. , The U.S. Apple Association – which represents apple growers and ...
(Date:1/17/2017)... ... , ... Gym Source, America’s leading retailer of premium residential and commercial fitness ... Miami, FL. , “We are elated to be opening this new showroom,” explains Tom ... to give clients a seamless and motivating shopping experience.” , Every fitness journey is ...
(Date:1/17/2017)... ... January 17, 2017 , ... Today, to ... Carol Francis re-releases powerfully uplifting interview with medical expert and prolific author, Dr. ... and pass through tough times, Dr. Bernie Siegel energizes listeners to live life ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... YORK , Jan. 17, 2017 North ... GlobalData,s new report, "North America Insulin Delivery Market ... North America Insulin Delivery market. The report provides value, ... average prices (USD) within market segments - Insulin Pens, ... The report also provides company shares and distribution ...
(Date:1/17/2017)... , Jan 17, 2017 Research and Markets ... System Market 2016-2020" report to their offering. ... The global artificial pancreas devices ... period 2016-2020. Global Artificial Pancreas Devices System Market 2016-2020, ... from industry experts. The report covers the market landscape and its ...
(Date:1/17/2017)... DUBLIN , Jan 17, 2017 ... for Self Healing Materials: 2017 - 2024" report to their ... This ... last full market report that was issued in May of 2015. ... market potential. In our previous analysis we projected a market potential ...
Breaking Medicine Technology: